Sign In
Buy PLX
$1.96
-0.0300 (-1.51%)
At Close: Jun 03, 2026
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
10:11am, Thursday, 13'th Nov 2025
Protalix BioTherapeutics, Inc. ( PLX ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Mike Moyer Dror Bashan - President, CEO & Director Gilad Mamlok - Senior VP & CFO Confer
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
06:50am, Thursday, 13'th Nov 2025
Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company foc
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
10:50am, Wednesday, 05'th Nov 2025
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioThera
Protalix and Chiesi seek EMA re-examination of Elfabrio dosing opinion
09:00am, Tuesday, 04'th Nov 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) and Chiesi Global Rare Diseases said they have requested a re-examination of a recent negative opinion by the European Medicines Agency's (EMA) Committee for
-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU -- -- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
08:31pm, Friday, 31'st Oct 2025
LOS ANGELES--(BUSINESS WIRE)---- $PLX--PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are a
Protalix BioTherapeutics (NYSE:PLX) vs. Invizyne Technologies (NASDAQ:IZTC) Critical Survey
02:36am, Sunday, 26'th Oct 2025
Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and Invizyne Technologies (NASDAQ: IZTC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
10:00am, Thursday, 23'rd Oct 2025
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are a
Why Is Protalix BioTherapeutics Stock Falling On Friday?
11:23am, Friday, 17'th Oct 2025
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for Protalix BioTherapeutics, Inc.'s (NYSE:PLX) and Chiesi Group's partne
Protalix, Chiesi reaffirm commitment to Fabry disease patients after EMA panel setback
08:26am, Friday, 17'th Oct 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX) and Chiesi Global Rare Diseases said they remain committed to advancing treatment options for Fabry disease after a European Medicines Agency committee declin
Every two weeks remains approved as a dosing regimen of Elfabrio in the EU Every two weeks remains approved as a dosing regimen of Elfabrio in the EU
Protalix BioTherapeutics to Present at Investor Summit Virtual
10:55am, Thursday, 11'th Sep 2025
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of
Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp
06:57am, Monday, 25'th Aug 2025
Protalix BioTherapeutics uses a plant-cell approach with ProCellEx. This has given it two approved ERTs plus PRX-115 and PRX-119. Its main focus is on a growing rare-disease pipeline. The main value d
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
12:47pm, Thursday, 14'th Aug 2025
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Dror Bashan - President, CEO & Director Eyal Rubin - Senior VP, CFO, Treasurer & Corpor
